WeightWatchers stock rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'
WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The weight-loss company, previously championed by the likes of Oprah Winfrey, saw its stock spike this week after announcing that it will make copycats of Novo Nordisk's (NVO) Ozempic and Wegovy weight-loss drugs.
WeightWatchers’ stock soars after adding compounded GLP-1 treatment to its offering
With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Executive Tara Comonte in prepared remarks.
WeightWatchers Adds Compounded GLP-1, Expanding Accessibility and Affordability of Weight Loss Medications
WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) announced today the addition of compounded semaglutide into its offering, broadening eligible members’ access to clinical weight management interventions that are underpinned by the comprehensive,
WeightWatchers stock pops on compounded GLP-1 weight-loss medication
Shares of WeightWatchers (WW) are climbing after the company announced a compounded GLP-1 medication starting at $129 as it seeks to make the weight-management solution "accessible and affordable." Catalysts Hosts Seana Smith and Madison Mills report more on the story and how it can compete with GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Ozempic and Eli Lilly's (LLY) Mounjaro.
WeightWatchers to offer compounded weight-loss drugs
WeightWatchers will begin selling compounded alternatives to certain weight-loss drugs that are experiencing shortages. Why it matters: Federal law allows companies to sell compounded versions of drugs that are on the FDA's shortages list — which has led to a surge of copycats to the newly popular class of GLP-1 injections.
WeightWatchers offers version of Ozempic, despite FDA concerns
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA say those versions come with risks.
WeightWatchers offering compounded version of Ozempic, despite concerns expressed by FDA
High demand has created a market for compounded versions of the drug best known as Ozemic or Wegovy, but doctors and the FDA ...
WeightWatchers Launches $129 Ozempic Alternative Amid Shortages
In response to rising demand for weight loss medications, WeightWatchers has launched a low-cost alternative to ...
WeightWatchers stock soars, but its cheap Wegovy knockoff 'is not a sustainable long-term business model'
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...
WeightWatchers cashes in on popularity of weight loss drugs with compounded semaglutide
WW International (NASDAQ:WW), more commonly known as WeightWatchers, will now offer compounded semaglutide to its ...
4029tv4d
The end of a shortage of popular weight-loss drugs may mean many people lose access to them
WEIGHT WATCHERS SAYS IT WILL NOW OFFER ELIGIBLE MEMBERS COMPOUNDED ... It's part of a class of drugs known as GLP-1 ...
What's Going With WeightWatchers Stock On Wednesday?
WeightWatchers stock rises after the company announces compounded semaglutide offerings, addressing GLP-1 shortages while ...